RT Journal Article
SR Electronic
T1 Association between NSAIDs use and adverse clinical outcomes among adults hospitalised with COVID-19 in South Korea: A nationwide study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.01.20119768
DO 10.1101/2020.06.01.20119768
A1 Jeong, Han Eol
A1 Lee, Hyesung
A1 Shin, Hyun Joon
A1 Choe, Young June
A1 Filion, Kristian B.
A1 Shin, Ju-Young
YR 2020
UL http://medrxiv.org/content/early/2020/06/02/2020.06.01.20119768.abstract
AB BACKGROUND Non-steroidal anti-inflammatory drugs (NSAIDs) may exacerbate COVID-19 and worsen associated outcomes by upregulating the enzyme that SARS-CoV-2 binds to enter cells. However, to our knowledge, no study has examined the association between NSAID use and the risk of COVID-19-related outcomes among hospitalised patients.METHODS We conducted a population-based cohort study using South Korea’s nationwide healthcare database, which contains data of all subjects who received a test for COVID-19 (n = 69,793) as of April 8, 2020. We identified a cohort of adults hospitalised with COVID-19, where cohort entry was the date of hospitalisation. NSAIDs users were those prescribed NSAIDs while hospitalised and non-users were those not prescribed NSAIDs. Our primary outcome was a composite of death, intensive care unit admission, mechanical ventilation use, and sepsis; secondary outcome was cardiovascular or renal complications. We conducted logistic regression analysis to estimate adjusted odds ratio (aOR) with 95% confidence intervals (CI) for the risk of these outcomes associated with NSAIDs users versus non-users, using propensity score–inverse probability of treatment weighting to minimize potential confounding. In sensitivity analyses, we compared NSAIDs to paracetamol (acetaminophen) to minimize confounding by indication.FINDINGS Of 1,824 adults hospitalised with COVID-19 (mean age 44.7 years; female 59%), 285 were NSAIDs users and 1,539 were non-users. Compared with non-users, NSAIDs users were associated with increased risks of the primary composite outcome (aOR 1.54, 95% CI 1.11–2.15) and cardiovascular or renal complications (aOR 2.64, 95% CI 1.67–4.16). The association with primary outcome remained consistent when comparing NSAIDs to paracetamol (aOR 1.31, 95% CI 0.89–1.95).INTERPRETATION Use of NSAIDs, compared with non-use, is associated with worse outcomes among hospitalised COVID-19 patients. While awaiting the results of confirmatory studies, we suggest NSAIDs be used with caution as the harms associated with their use may outweigh their benefits in this population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFUNDING: Government-wide R&D Fund for Infectious Disease Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of Sungkyunkwan University (SKKU 2020-03-012) and obtaining informed consent was waived by the board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo additional data available.